Articles related to PANCREATIC CANCER

Daraxonrasib produced 13.2-month median overall survival versus 6.7 months with chemotherapy in 501 previously treated metastatic pancreatic ductal adenocarcinoma patients in the phase 3 RASolute 302 trial.

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

When glutamate binds to the cancer cells’ NMDA receptors, a channel opens and calcium flows into the cell. This influx triggers molecular signaling cascades that drive tumor growth and metastasis.

Early detection improves the prognosis, and treatment may involve surgery, radiation, or chemotherapy.

ALK7 gives pancreatic cancer cells both the engine to move and the tools to invade…But if we can inhibit ALK7 at the cancer’s earliest and most vulnerable stage, we might see better outcomes for patients.

The modified Johns Hopkins procedure demonstrates how robotic assistance can enhance surgical precision through small incisions, potentially reducing trauma and accelerating recovery in suitable pancreatic cancer patients.